Xarelto Patent Protection

The Xarelto record above pulls directly from the FDA Orange Book and USPTO patent records. What follows is the per-entity context — how Xarelto sits in the broader U.S. pharmaceutical patent expirations distribution and which underlying factors drive the headline numbers.

The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for Xarelto is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.